Company Overview of Immunovative Therapies Ltd.
Immunovative Therapies Ltd., a biopharmaceutical company, develops products to treat adult patients in Israel. It specializes in the development of immunotherapy drug products that incorporate living immune cells as active ingredients for the treatment of cancer and infectious disease. Its products include AlloStim, which contains activated T-Stim cells that are formulated for infusion; CryoStim, an in-situ therapeutic cancer vaccine for patients with disseminated metastatic tumors; and AlloVax, an individualized anti-cancer vaccine to educate the immune system during the period of cancer remission to prevent the tumor from recurring. The company develops protocols for patients with various ...
P.O. Box 974
Founded in 2004
Key Executives for Immunovative Therapies Ltd.
Founder and Chief Executive Officer
Chairman of Immunovative Inc and Chief Executive Officer of Immunovative Inc
Chairman of the Scientific Advisory Board
Director of Regulatory Affairs and Clinical Operations
Compensation as of Fiscal Year 2014.
Immunovative Therapies Ltd. Key Developments
Immunovative, Inc. Enters into Settlement Agreement with Immunovative Therapies Ltd
Feb 20 13
On January 14, 2013, Immunovative Inc. received a notice from Immunovative Therapies Ltd. purporting to terminate the license agreement dated December 9, 2011 between the company and Immunovative Therapies Ltd. On January 16, 2013, the company filed an action against Immunovative Therapies Ltd. in the United States District Court of the Southern District of New York alleging various damages and seeking injunctive relief against Immunovative Therapies Ltd. On February 19, 2013, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability, breach, or wrongdoing, the company entered into a Settlement Agreement and Release with Immunovative Therapies Ltd. The Settlement Agreement resolves all claims brought by the company against Immunovative Therapies Ltd., will result in the company dismissing its claims against Immunovative Therapies Ltd. with prejudice and will prevent Immunovative Therapies Ltd. from bringing any counterclaims against the company. As part of the Settlement Agreement, Immunovative Therapies Ltd. has agreed to provide the company an immaterial cash payment and grant the company a 9% equity interest in Immunovative Therapies Ltd.
Immunovative, Inc. Files Lawsuit Against Immunovative Therapies Ltd
Jan 17 13
Immunovative Inc. announced that the company has filed a lawsuit against Immunovative Therapies Ltd. in the U.S. District Court for the Southern District of New York. The lawsuit alleges that ITL wrongfully terminated the License Agreement between ITL and the company. The suit seeks the imposition of an equitable lien on with respect to the patents, intellectual property, and scientific work funded by the company. In the alternative, the suit seeks return of approximately $3.7 million paid by the company to ITL to fund its scientific work, compensatory damages, and an equity interest in ITL as provided by the License Agreement.
Immunovative, Inc. Announces Termination of License Agreement with Immunovative Therapies Ltd
Jan 9 13
Immunovative Inc. announced that on January 8, 2013, it received from Immunovative Therapies Ltd. a notice that purports to terminate effective immediately the license agreement dated as of December 9, 2011, between the company and ITL. The notice alleges numerous purported breaches of the license agreement, mainly with respect to the administration and timing of payments from the company to ITL. It also demands immediate payment of approximately $4.15 million from the company to ITL for what it claims to be damages suffered by ITL.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|